Literature DB >> 3524920

The syndrome of hypertension and hyperkalaemia with normal GFR. A unique pathophysiological mechanism for hypertension?

R D Gordon.   

Abstract

Based on 28 reported patients, constant features of the syndrome of hypertension and hyperkalaemia are hyperkalaemia, hyperchloraemia, normal renal glomerular function and, in all adult patients, hypertension. Inconstant features include short stature, intellectual impairment and muscle weakness. Levels of renin and aldosterone are low, but respond to dietary salt restriction and diuretic therapy, both of which reverse the hypertension and hyperkalaemia. The basic abnormality is excessive renal sodium retention, leading to chronic suppression of renin and aldosterone; the latter is then hyporesponsive to the hyperkalaemic stimulus. Dietary salt loading or impaired production of any natriuretic or chloriuretic factor (for example atrial natriuretic peptide or renal natriuretic prostaglandins) would predispose to development of the syndrome. With normal GFR, this appears to be a unique mechanism for hypertension and hyperkalaemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524920     DOI: 10.1111/j.1440-1681.1986.tb00358.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

1.  Potassium Homeostasis, Oxidative Stress, and Human Disease.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  Int J Clin Exp Physiol       Date:  2017

Review 2.  Regulation of Potassium Homeostasis.

Authors:  Biff F Palmer
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

3.  NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.

Authors:  Omar A Z Tutakhel; Arthur D Moes; Marco A Valdez-Flores; Marleen L A Kortenoeven; Mathijs V D Vrie; Sabina Jeleń; Robert A Fenton; Robert Zietse; Joost G J Hoenderop; Ewout J Hoorn; Luuk Hilbrands; René J M Bindels
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.